supplied by www.ccc.ac.at

5 Einträge

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Autoren Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ
Erscheinungsdaten The New England journal of medicine. 2015 Sep 25. doi: 10.1056/NEJMoa1510016
Publikations ID PMID: 26406150
 


Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Autoren Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ
Erscheinungsdaten The Lancet. Oncology. 2016 Jun 3. pii: S1470-2045(16)30107-3. doi: 10.1016/S1470-2045(16)30107-3
Publikations ID PMID: 27279544
 


Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Autoren Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Vuillemin AT, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jul 11. pii: JCO.2015.65.5597. doi: 10.1200/JCO.2015.65.5597
Publikations ID PMID: 27400947
 


Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Autoren Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A
Erscheinungsdaten The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9
Publikations ID PMID: 29146401
 


Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Autoren Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK
Erscheinungsdaten Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 29. doi: 10.1200/JCO.2017.75.2170
Publikations ID PMID: 29377755